XML 26 R16.htm IDEA: XBRL DOCUMENT v3.19.1
Summary of Significant Accounting Policies (Tables)
3 Months Ended
Mar. 31, 2019
Accounting Policies [Abstract]  
Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis

The following table provides a summary of financial instruments that are measured at fair value as of March 31, 2019.

 

    Carrying     Fair Value Measurement Using  
    Value     Level 1     Level 2     Level 3     Total  
                               
Marketable securities                              
Derivative warrants liabilities   $ (626,677 )   $     $     $ (626,677 )   $ (626,677 )

 

The following table provides a summary of financial instruments that are measured at fair value as of December 31, 2018.

 

    Carrying     Fair Value Measurement Using  
    Value     Level 1     Level 2     Level 3     Total  
                               
Marketable securities     250,388       250,388                   250,388  
Derivative warrants liabilities   $ (676,079 )   $     $     $ (676,079 )   $ (676,079 )

Schedule of Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation

The table below provides a summary of the changes in fair value, including net transfers in and/or out, of all financial assets and liabilities measured at fair value on a recurring basis using significant unobservable inputs (Level 3) during the three months ended March 31, 2019 and the year ended December 31, 2018:

 

   

Fair Value Measurement

Using Level 3

 
    Inputs Total  
Balance, December 31, 2017   $ 425,838  
Change in fair value of derivative warrants liabilities     (250,241 )
Balance, December 31, 2018     676,079  
Change in fair value of derivative warrants liabilities     (49,402 )
Balance, March 31, 2019   $ 626,677  

Schedule of Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques

    December 31, 2018     March 31, 2019  
Exercise price     1.25       1.25  
Risk free interest rate     2.46 %     2.67 %
Dividend yield     0.00 %     0.00 %
Expected volatility     152 %     138 %
Contractual term     2.15 Years       1.90 Years  

Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share

The effect of dilution on net loss becomes anti-dilutive and therefore is not reflected on the income statement.

 

    Potentially Outstanding
Dilutive Common Shares
 
    For the Three Months Ended
March 31, 2019
    For the Year
Ended
December 31, 2018
 
             
Conversion Feature Shares                
                 
Common shares issuable under the conversion feature of preferred shares     872,766       872,766  
                 
Stock Option     3,947,866       3,846,299  
                 
Warrant     3,826,658       3,826,658  
                 
Total potentially outstanding dilutive common shares     8,647,290       8,545,723